Shell Asset Management Co. Purchases 5,626 Shares of Boston Scientific Co. (NYSE:BSX)

Shell Asset Management Co. boosted its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 32.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,120 shares of the medical equipment provider's stock after acquiring an additional 5,626 shares during the quarter. Shell Asset Management Co.'s holdings in Boston Scientific were worth $2,065,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Capital Investment Advisors LLC lifted its holdings in shares of Boston Scientific by 12.2% during the 4th quarter. Capital Investment Advisors LLC now owns 2,899 shares of the medical equipment provider's stock valued at $259,000 after buying an additional 315 shares during the period. Accurate Wealth Management LLC purchased a new position in shares of Boston Scientific in the fourth quarter worth approximately $228,000. Kathmere Capital Management LLC grew its position in Boston Scientific by 29.7% during the fourth quarter. Kathmere Capital Management LLC now owns 4,510 shares of the medical equipment provider's stock valued at $403,000 after buying an additional 1,034 shares during the period. Park Avenue Securities LLC increased its holdings in Boston Scientific by 12.0% during the fourth quarter. Park Avenue Securities LLC now owns 12,869 shares of the medical equipment provider's stock valued at $1,149,000 after buying an additional 1,381 shares during the last quarter. Finally, Burney Co. raised its position in Boston Scientific by 15.3% in the fourth quarter. Burney Co. now owns 10,192 shares of the medical equipment provider's stock worth $910,000 after acquiring an additional 1,350 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, April 29th. Evercore ISI boosted their price target on Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Wells Fargo & Company upped their price target on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Raymond James lifted their price objective on Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research report on Thursday, February 6th. Finally, Morgan Stanley boosted their price objective on Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, May 16th. Twenty-three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $114.74.

Boston Scientific Price Performance

Shares of NYSE:BSX traded down $0.26 during mid-day trading on Thursday, reaching $104.38. The stock had a trading volume of 1,941,206 shares, compared to its average volume of 7,641,952. The business's 50 day moving average price is $99.76 and its 200 day moving average price is $97.02. Boston Scientific Co. has a 1 year low of $71.88 and a 1 year high of $107.17. The company has a market cap of $154.43 billion, a P/E ratio of 83.51, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. The business had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company's revenue for the quarter was up 20.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.56 EPS. Research analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,314 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the sale, the executive vice president now directly owns 22,235 shares in the company, valued at $2,269,304.10. This represents a 43.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Vance R. Brown sold 4,826 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the sale, the senior vice president now directly owns 36,193 shares of the company's stock, valued at $3,441,592.37. The trade was a 11.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 195,830 shares of company stock worth $20,043,415 over the last 90 days. 0.50% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.